Safety assessment of neoantigen peptides-loaded dendritic cell vaccination therapy.
Phase 1
- Conditions
- Malignant tumor (except leukemia)
- Registration Number
- JPRN-UMIN000035020
- Lead Sponsor
- Bio-Thera Clinic
- Brief Summary
eoantigen DCs would be a safe treatment method. Neoantigen DCs would induce the acquisition of immune reaction against neoantigens.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
A patient must not: - be impossible to obtain blood sample by Leukapeheresis. - be positive in HIV antibody test. - have active auto-immune disorder. - have serious underlying disease. - be pregnant (including pregnancy seeker) - be judged ineligibles by clinician in this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method